Source: Media Outreach
Patent adds to company’s robust portfolio covering clinical stage lead development candidate PD01
VIENNA, AUSTRIA – EQS Newswire – March 3, 2020 – AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, today announces the award of a new patent by the Chinese National Intellectual Property Administration (CNIPA). The patent covers a group of AFFITOPEs, including PD01, the Company’s lead candidate for the treatment of early-stage Parkinson’s disease patients which is expected to enter clinical phase 2 in the second half of 2020.
AFFiRiS, which has already obtained patents in the United States, Europe, Australia, Canada, India, Japan and South Korea for the same application, thus further expand the geographic coverage of its intellectual property portfolio thanks to this new patent. In addition, the newly granted IP adds to AFFiRiS’ broad patent position covering the treatment of Parkinson’s disease, and its product candidate PD01, as well as to its overall body of patents and patent applications, reflecting the excellent competitive profile in the field of neurodegenerative treatments.
“This new patent strengthens the position of our lead candidate, PD01, which we will move into phase 2 of clinical development for the treatment Parkinson’s disease, an indication with an urgent and significant unmet medical need,” said Noel Barrett, Ph.D., AFFiRiS’ Chief Executive Officer. “Importantly, the new IP supports us in the growth of our business in the highly attractive Chinese market.”
AFFiRiS recently received positive FDA responses to its pre-Investigational New Drug (“IND”) submission for the phase 2 trial with AFFITOPE(R) PD01 in early Parkinson’s disease patients. The active immunotherapy candidate PD01 is based on AFFiRiS’ AFFITOPE(R) technology, which is also covered by this new patent.
The new patent CN 101969989 (also published as WO 2009/103105) describes how AFFiRiS’ AFFITOPE(R) compounds may prevent and/or treat neurodegenerative disorders characterized by pathological accumulation of alpha-synuclein aggregates, commonly referred to as synucleinopathies, including Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB), as well as Multiple System Atrophy (MSA) or Neurodegeneration with Brain Iron Accumulation type I (NBIA Type I).
The issuer is solely responsible for the content of this announcement.
– Published and distributed with permission of Media-Outreach.com.
